Inclusion Criteria:  Pregnant women with prenatal discovery of fetal malformations on ultrasound that may justify the performance of a fetal exome sequencing (e.g., multiple malformations and/or severe brain malformation, microphthalmia, bone damage, severe cardiac damage, etc.) and who will have or are having an invasive prenatal sample for array CGA diagnosis Sufficient quantity of fetal sample (amniotic fluid or fetal blood or fetal DNA) for the collection of an additional sample for the ES Ability to collect blood samples from the pregnant woman and the biological father of the fetus (peripheral blood) Pregnant woman and father of the fetus aged ≥18 years Pregnant woman and father of the fetus able to comprehend the situation Person who has provided written consent  Exclusion Criteria:  - Refusal of the pregnant woman or biological father to participate in the study Pregnancy before 11 weeks of amenorrhea or after 34 weeks of amenorrhea (to limit the risk of reporting results after birth) Pregnant women and/or biological fathers who are not affiliated to the national health insurance systel Pregnant women and/or biological fathers under some type of legal protection (guardianship, trusteeship, etc.) Pregnant women and/or biological fathers who are unable to express their consent  Organizational pilot study:  In addition to the inclusion & exclusion criteria of the main study:  Pregnant woman and biological father of fetus who provided oral consent to be interviewed Professionals (obstetrician, midwife, geneticist, biologist) willing to be interviewed